ARBs

The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...


Angiotensin converting enzyme inhibitors ( ACE inhibitors ) and angiotensin receptor blockers ( ARBs; sartans ) are widely prescribed for...


In the Ongoing Telmisartan Alone and in Combination with Ramipril Trial ( ONTARGET ), dual agent renin-angiotensin-aldosterone system ( RAAS...


In the ONTARGET ( Ongoing Telmisartan Alone and in Combination with Ramipril Trial ) trial, dual agent renin-angiotensin-aldosterone system (...


Enzyme replacement therapy ( ERT ) is the standard therapy for Fabry disease. Enzyme replacement therapy partially cleared microvascular deposits...


Combination therapy with angiotensin-converting–enzyme ( ACE ) inhibitors and angiotensin-receptor blockers ( ARBs, sartans ) decreases proteinuria; however, its safety...


The EMA ( European Medicines Agency ) has finalised a review of Aliskiren-containing medicines, recommending that these medicines should be...


Myocardial infarction strikes some 865,000 Americans each year. Treating patients with scientifically proven therapies both in the hospital and at...


A one-year pilot study examined the effect of Ruboxistaurin ( Arxxant ) in patients with type 2 diabetes and diabetic...


Heart failure is associated with a high death rate. Medications shown to reduce the risk of illness and death from this...